ROCHE PROVIDES UPDATE ON ONCOLOGY PIPLINE

A A

Roche took the opportunity to reassure investors and analysts as it outlined its plans to deal with the impending threat to Avastin and Herceptin. Roche's new indications for cancer treatments suggest that its oncology portfolio will show strong growth for many years.

In-PharmaTechnologist.com (http://www.in-pharmatechnologist.com/news/ng.asp?n=68747-roche-xeloda-avastin)